Skip to main content

Advertisement

Log in

Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Based on the presence of the tumor-specific over-expression of Plk1 (polo-like kinases) in various malignancies, we examined Plk1 expression in nine cases of reactive follicular hyperplasia (RFH), 42 of diffuse large B cell lymphoma (DLBCL), 16 of follicular lymphoma (FL), and 10 of nasal NK/T lymphoma. There was no significant difference in the Plk1-positive cell percentage between RFH and DLBCL. The Plk1-positive cell percentage ranged from 6 to 20% with a median of 12.9% in DLBCL. In FL, Plk1-positivity was at most 7%. Plk1-positivity in nasal NK/T cell lymphoma (4.7–14.1% with a median of 9.2%) was significantly higher than that of FL and tended to be lower than DLBCL (p < 0.001, p = 0.05, respectively). Although a strong correlation between positive cell percentages for Plk1 and Ki-67 in these three lymphomas specified Plk1 as a proliferation marker (r = 0.83–0.91), the Plk1-positive cell percentage relative to the other proliferation markers tended to be particularly low in nasal NK/T cell lymphoma. In 41 cases of DLBCL, the positive cell percentages of Plk1 and Ki-67 were both correlated with overall survival. The 4-year overall survival rates by Kaplan–Meier analysis for Plk1-negative and positive patients were 80 and 38%, respectively (p = 0.02).

This is a preview of subscription content, log in via an institution to check access.

Access this article

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Barr FA, Silljé HHW, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004;5:429–41. doi:10.1038/nrm1401.

    Article  PubMed  CAS  Google Scholar 

  2. Silljé HHW, Nigg EA. Capturing polo kinase. Science. 2003;21:1190–1. doi:10.1126/science.1082384.

    Article  Google Scholar 

  3. Glover DM, Ohkura H, Tavares Á. Polo kinase: the choreographer of the mitotic stage? J Cell Biol. 1996;135:1681–4. doi:10.1083/jcb.135.6.1681.

    Article  PubMed  CAS  Google Scholar 

  4. Cárcer G. Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner. Cancer Res. 2004;64:5106–12. doi:10.1158/0008-5472.CAN-03-2214.

    Article  PubMed  Google Scholar 

  5. Lee KS, Grenfell TG, Yarm FR, Erikson RL. Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. Proc Natl Acad Sci USA. 1998;95:9301–6. doi:10.1073/pnas.95.16.9301.

    Article  PubMed  CAS  Google Scholar 

  6. Liu X, Erikson RL. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc Natl Acad Sci USA. 2002;99:8672–6. doi:10.1073/pnas.132269599.

    Article  PubMed  CAS  Google Scholar 

  7. Liu X, Erikson RL. Polo-like kinase (Plk) 1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA. 2003;100:5789–94. doi:10.1073/pnas.1031523100.

    Article  PubMed  CAS  Google Scholar 

  8. Donaldson MM, Tavares ÁAM, Ohkura H, Deak P, Glover DM. Metaphase arrest with centromere Separation in polo mutants of Drosophila. J Cell Biol. 2001;153:663–75. doi:10.1083/jcb.153.4.663.

    Article  PubMed  CAS  Google Scholar 

  9. Seong YS, Kamijo K, Lee JS, Fernandez E, Kuriyama R, Miki T, et al. A spindle checkpoint arrest and cytokinesis failure by the dominant- negative Polo-box domain of Plk1 in U-2 OS cells. J Biol Chem. 2002;277:32282–93. doi:10.1074/jbc.M202602200.

    Article  PubMed  CAS  Google Scholar 

  10. Smits VAJ, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol. 2000;2:672–6. doi:10.1038/35023629.

    Article  PubMed  CAS  Google Scholar 

  11. Ree AH, Bratland Å, Nome RV, Stokke T, Fodstad Ø. Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1. Oncogene. 2003;22:8952–5. doi:10.1038/sj.onc.1207000.

    Article  PubMed  CAS  Google Scholar 

  12. Smith MR, Wilson ML, Ryoji H, Chase D, Kung HF, Longo DL, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun. 1997;234:397–405. doi:10.1006/bbrc.1997.6633.

    Article  PubMed  CAS  Google Scholar 

  13. Wolf G, Elez R, Doemer A, Holtrich U, Ackermann H, Stutte HJ, et al. Prognostic significance of polo-like kinase (Plk) expression in non-small cell lung cancer. Oncogene. 1997;14:543–9. doi:10.1038/sj.onc.1200862.

    Article  PubMed  CAS  Google Scholar 

  14. Weichert W, Kristiansen G, Winzer KJ, Schmidt M, Gekeler V, Noske A, et al. Polo-like kinases isoforms in breast cancer: expression patterns and prognostic implication. Virchows Arch. 2005;446:442–50. doi:10.1007/s00428-005-1212-8.

    Article  PubMed  CAS  Google Scholar 

  15. Takahasi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 2003;94:148–52. doi:10.1111/j.1349-7006.2003.tb01411.x.

    Article  Google Scholar 

  16. Weichert W, Kristiansen G, Schmidt M, Gekeler V, Noske A, Niesporek S, et al. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol. 2005;11:5644–50.

    PubMed  CAS  Google Scholar 

  17. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol. 2002;29:354–8. doi:10.1034/j.1600-0560.2002.290605.x.

    Article  PubMed  Google Scholar 

  18. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene. 2005;24:287–91. doi:10.1038/sj.onc.1208272.

    Article  PubMed  CAS  Google Scholar 

  19. Anger M, Kues WA, Klima J, Mielenz M, Kubelka M, Motlik J, et al. Cell cycle dependent expression of Plk1 in synchronized porcine fetal fibroblasts. Mol Reprod Dev. 2003;65:245–53. doi:10.1002/mrd.10289.

    Article  PubMed  CAS  Google Scholar 

  20. Golsteyn RM, Mundt KE, Fry AM, Nigg EA. Cell cycle regulation of the activity and subcellular localization of PLK1, a human protein kinase implicated in mitotic spindle function. J Cell Biol. 1995;129:1617–28. doi:10.1083/jcb.129.6.1617.

    Article  PubMed  CAS  Google Scholar 

  21. Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I, Yokoyama S. Expression of Polo-like kinase(PLK1) in non-Hodgkin’s lymphomas. Leuk Lymphoma. 2005;46:225–31. doi:10.1080/10428190400015709.

    Article  PubMed  CAS  Google Scholar 

  22. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, German Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82. doi:10.1182/blood-2003-05-1545.

    Article  PubMed  CAS  Google Scholar 

  23. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate. 2004;60:240–5. doi:10.1002/pros.20050.

    Article  PubMed  CAS  Google Scholar 

  24. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin lymphomas: a prospective Southwest Oncology Group Trial. Blood. 1994;83:1460–6.

    PubMed  CAS  Google Scholar 

  25. Grogan TM, Lippman SM, Spier CM, Slymen DJ, Rybski JA, Rangel CS, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphoma as determined by the monoclonal antibody Ki-67. Blood. 1988;71:1157–60.

    PubMed  CAS  Google Scholar 

  26. Slymen DJ, Miller TP, Lippman SM, Spier CM, Kerrigan DP, Rybski JA, et al. Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol. 1990;8:986–93.

    PubMed  CAS  Google Scholar 

  27. Seki R, Okamura T, Koga H, Yakushiji K, Hashiguchi M, Yoshimoto K, et al. Prognostic significance of the F-Box protein Skp2 expression in diffuse large B-cell lymphoma. Am J Hematol. 2003;73:230–5. doi:10.1002/ajh.10379.

    Article  PubMed  Google Scholar 

  28. Hans CP, Weisenburger DD, Greiner TC, Chan WC, Aoun P, Cochran GT, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol. 2005;18:1377–84. doi:10.1038/modpathol.3800434.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Ms Mitsuko Hosoi for her excellent technical assistance.

Conflict of interest statement

K. T. is a consultant for DAKO.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Koichi Sugimoto.

About this article

Cite this article

Imai, H., Sugimoto, K., Isobe, Y. et al. Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. Int J Hematol 89, 673–678 (2009). https://doi.org/10.1007/s12185-009-0325-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-009-0325-2

Keywords

Navigation